中药治疗 COVID-19 的药代动力学和代谢。
Pharmacokinetics and Metabolism of Traditional Chinese Medicine in the Treatment of COVID-19.
机构信息
Institute of Pharmaceutical Pharmacology, University of South China, Hengyang, China.
The Second Affiliated Hospital, University of South China, Hengyang, China.
出版信息
Curr Drug Metab. 2022;23(7):508-520. doi: 10.2174/1389200223666220630124403.
BACKGROUND
The outbreak of coronavirus disease 19 (COVID-19) has caused great concern to public health. Convincing clinical experiences showed that traditional Chinese medicine (TCM) has exhibited remarkable efficacy in the prevention, treatment and rehabilitation of COVID-19. The research on the treatment of COVID-19 disease with TCM mainly focused on the pharmacological effects and mechanistic analysis. However, the TCM's pharmacokinetics and potential herb-drug interaction in the treatment of COVID-19 are currently unclear.
METHODS
This review summarizes the pharmacokinetics and characteristics of cytochrome P450 enzyme (CYP450) metabolism of TCM recommended in the Guidelines for diagnosis and treatment of coronavirus disease 2019 (trial version eighth), and meanwhile analyzes the potential interactions between TCM and western medicine.
RESULTS
The pharmacokinetics of TCM mainly focused on preclinical pharmacokinetics, and fewer clinical pharmacokinetics research was reported. When TCM and western are both metabolized by CYP450 and coadministered, a potential herb-drug interaction might occur.
CONCLUSION
Knowledge of the pharmacokinetics and metabolism of TCM is key to understanding rational TCM use of COVID-19 and developing antiviral TCM.
背景
新型冠状病毒肺炎（COVID-19）的爆发引起了公众健康的极大关注。令人信服的临床经验表明，中医药在 COVID-19 的预防、治疗和康复方面显示出了显著的疗效。针对 COVID-19 疾病的中医药治疗主要集中在药理学作用和机制分析上。然而，中医药在治疗 COVID-19 中的药代动力学和潜在的药物相互作用目前尚不清楚。
方法
本综述总结了《新型冠状病毒肺炎诊疗方案（试行第八版）》中推荐的中医药的药代动力学和细胞色素 P450 酶（CYP450）代谢特征，并同时分析了中医药与西药之间的潜在相互作用。
结果
中医药的药代动力学主要集中在临床前药代动力学研究，而报告的临床药代动力学研究较少。当中医药和西药都由 CYP450 代谢并同时给药时，可能会发生潜在的药物-药物相互作用。
结论
了解中医药的药代动力学和代谢特征是理解 COVID-19 中合理使用中医药和开发抗病毒中医药的关键。
Zotero 插件